The Seraseq Tumor Mutation DNA Mix v2 (AF4) LC is a multiplexed mixture of actionable biosynthetic DNA targets precisely blended with a single, well-characterized genomic background to an allelic frequency of 4%, offered in a low concentration (LC) at 5 ng/µL for assays that have lower input DNA requirements. Designed to assess the overall performance of your somatic mutation assay by next-generation sequencing (NGS), this unique product includes a wide range of single nucleotide variants (SNVs), insertion-deletion mutations (indels), and structural variants (SVs).
Single-vial format for daily run use
40 unique multiplexed variants across 28 genes (see table in Specifications tab)
5 SNVs that are part of homopolymers
Mutation targets quantitated with digital PCR
Well-characterized GM24385 human genomic DNA as background wild-type material
Manufactured within cGMP-compliant, ISO 13485-certified facilities
The Seraseq Tumor Mutation DNA Mix v2 (AF4) LC is formulated for use with targeted next-generation sequencing (NGS) assays that detect mutations in key oncogenes and tumor suppressor genes. The Seraseq Tumor Mutation DNA Mix v2 (AF4) LC is intended as a quality reference material for translational and disease research testing to monitor library preparation, sequencing, and variant allele detection under a given set of bioinformatics pipeline parameters.
For research use only. Not for use in diagnostic procedures.